Steven O’Day: March is Colorectal Cancer Awareness Month—a time where I am reminded of the resilience and courage of those affected by this disease

Steven O’Day shared on LinkedIn:

“March is Colorectal Cancer Awareness Month—a time where I am reminded of the resilience and courage of those affected by this disease.

Throughout the month, I am joining patients, caregivers, and healthcare professionals in our collective fight against colorectal cancer. As the second leading cause of cancer deaths in the United States, and with diagnoses on the rise among younger adults, colorectal cancer demands our attention.
I am proud to be a part of Agenus’ mission to research and develop immunotherapies for those facing this disease.

Join me in raising awareness and working toward making a tangible difference in the lives of those affected by colorectal cancer.”

Source: Steven O’Day/LinkedIn

Steven O’Day serves as Agenus’ Chief Medical Officer. He is responsible for leading the expansion of the company’s presence in the I-O field. A pioneer in CTLA-4 inhibition, Dr O’Day played key roles in the advancement of cancer therapies Yervoy and Opdivo, and has been the principal investigator in more than 200 clinical trials. Prior to joining Agenus, he was Executive Director of the John Wayne Cancer Institute and Cancer Clinics at Providence St. John’s Health Center, and Director of the Melanoma and Cutaneous Oncology Research Center. Steven was a visiting scholar in philosophy and medical ethics at Oxford, received his MD from Johns Hopkins, and was a Fellow at the Dana Farber/Harvard Cancer Center.